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ABSTRACT The herpes simplex virus 1 (HSV-1) is widespread in the population, and
in most cases its infection is asymptomatic. The currently available anti-HSV-1 drugs
are acyclovir and its derivatives, although long-term therapy with these agents
can lead to drug resistance. Thus, the discovery of novel antiherpetic compounds de-
serves additional effort. Naturally occurring antimicrobial peptides (AMPs) represent
an interesting class of molecules with potential antiviral properties. To the best of
our knowledge, this study is the first demonstration of the in vitro anti-HSV-1 activity
of temporin B (TB), a short membrane-active amphibian AMP. In particular, when
HSV-1 was preincubated with 20 g/ml TB, significant antiviral activity was observed
(a 5-log reduction of the virus titer). Such an effect was due to the disruption of the
viral envelope, as demonstrated by transmission electron microscopy. Moreover, TB
partially affected different stages of the HSV-1 life cycle, including the attachment
and the entry of the virus into the host cell, as well as the subsequent postinfection
phase. Furthermore, its efficacy was confirmed on human epithelial cells, suggesting
TB as a novel approach for the prevention and/or treatment of HSV-1 infections.
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One of the most widespread human pathogens is the herpes simplex virus 1(HSV-1), an enveloped DNA virus whose primary infection generally occurs in the
oropharyngeal mucosa, followed by neuronal latency in the peripheral ganglia. Reac-
tivation of the latent results either in asymptomatic virus shedding or in recurrent
herpes disease (1–3). In most cases, HSV-1 infection is asymptomatic, and the majority
of people are unaware of their HSV-1 status. However, in immunocompromised indi-
viduals, HSV-1 recurrences are associated with severe symptoms and, rarely, continuous
virus reactivations can be the beginning of more serious complications, such as
encephalitis and keratitis (4). HSV-1 infections are usually treated with antiviral agents
such as acyclovir and its derivatives; unfortunately, these therapies neither prevent
recurrence arising from the reactivation of the latent virus, nor do they completely
eliminate the virus (5). Among immunocompetent patients, HSV-1 infection is con-
trolled rapidly by the human host’s immune system, thus requiring short-term antiviral
therapy with minimal risk of developing resistance. In contrast, immunocompromised
patients may be unable to control HSV-1 infection and generally need long-term
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antiherpetic therapy, which is more likely to induce drug resistance (6, 7). In this
context, it is essential to develop novel anti-HSV-1 agents.
Recently, naturally occurring antimicrobial peptides (AMPs) have been studied for
their potential antiviral properties, as demonstrated against several viruses (8–11).
AMPs are expressed in almost all living organisms, including plants and animals, as
conserved products of innate immunity (12). Frog skin is one of the richest sources of
AMPs that are synthesized by adrenergically innervated dermal glands and stored
within granules that are released onto the skin surface by a holocrine mechanism in
response to alarm or injury (13, 14). A family of amphibian AMPs, originally isolated
from the European red frog Rana temporaria, is called temporins. These peptides
represent the shortest AMPs found in nature to date with a typical length of 10 to 13
amino acids and a conserved sequence (15, 16). They are amidated at the C terminus
and are characterized by a weak cationic charge (net charge ranging from 2 to 3)
owing to the presence of only one or two positively charged amino acids, such as lysine
or arginine, in their sequence.
Temporins, like other AMPs, exert antimicrobial activity against bacteria and myce-
tes (17, 18), while their antiviral activity has been reported only against a few enveloped
or nonenveloped viruses of ectothermic animals (19). Furthermore, no studies regard-
ing the activity of temporins against human viruses have been reported to date.
Here, we demonstrate for the first time the in vitro antiviral activity of temporin B
(TB) against HSV-1. When added to HSV-1-infected cells, TB significantly reduced the
virus titer, but, more importantly, the greatest inhibition was obtained by preincubation
of HSV-1 with the peptide for 1 h at 37°C, thus demonstrating its virucidal activity.
RESULTS
Temporin B is not cytotoxic and reduces the HSV-1 titer. In a first set of
experiments, we evaluated the effect of TB on Vero cell viability. To do this, cells treated
with different concentrations (1 to 100 g/ml) of peptide for 24 h were stained with
trypan blue; their microscopic examination revealed no significant mortality in cells
treated with the peptide at a concentration up to 40 g/ml. In contrast, at higher
concentrations, morphological alterations, loss of cell viability, and modification of
the cell multiplication rate were observed (data not shown). These results were con-
firmed by means of an MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide]-based assay. As shown in Fig. 1A, cell proliferation was not affected by TB at
low doses, whereas it decreased in a dose-dependent manner starting from 50 g/ml.
The 50% cytotoxic concentration (CC50) for the peptide was 90.4 g/ml. On the basis
of these results, in order to evaluate the potential antiviral activity of TB against HSV-1,
we used the peptide at concentrations ranging from 0.1 to 40 g/ml. To do this, a
plaque reduction assay was performed. The results (Fig. 1B) indicate that TB reduced
the HSV-1 titer in a dose-dependent way. The 50% inhibitory concentration (IC50) was
2.507 g/ml (95% confidence interval  2.325 to 2.703; selectivity index [CC50/IC50] 
36.06). On the basis of the obtained results, the next experiments were performed using
TB at 20 g/ml.
TB affects life cycle and cell to cell spreading of HSV-1. To evaluate the effect of
TB on HSV-1 life cycle, Vero cells were infected with HSV-1 and incubated with TB at
different times as follows: (i) during the viral adsorption (1 h [ADS]), (ii) immediately
after viral adsorption (for 24 h [POST]), and (iii) during viral adsorption and for the
following 24 h (ADSPOST). The results showed that TB was effective in reducing HSV-1
titer of 1.5 log under all of the experimental conditions tested (Fig. 2, upper panel).
These results were confirmed through the analysis of infected cell proteins (ICPs) and
late structural viral proteins, including glycoprotein B (gB). As shown in Fig. 2 (lower
panel), the viral protein content was reduced in TB-treated cells under any condition
with respect to untreated infected cells. Interestingly, the highest inhibition was
obtained when the peptide was added as double doses (ADSPOST), as confirmed
by densitometric analysis of gB (an 2.5-fold reduction).
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On the basis of these results, we evaluated the effect of TB on HSV-1 cell-to-cell
spread. Indeed, it is known that gB, gD, gH, and gL are the principal HSV-1 glycopro-
teins required for virus entry into the cell and for cell-to-cell spread (20). To assess this
effect, confluent monolayer of Vero cells were treated or not with TB during viral
adsorption and for the following 24 h of infection. Moreover, some samples were also
incubated with HSV-1 neutralizing antibody to ensure that the occurred HSV-1 infection
was due to cell-to-cell spread. Immunostaining analysis using a LI-COR Odyssey infrared
imaging system (Fig. 3) revealed that neutralizing antibody and TB were able to reduce
the foci of infection by about 20 and 50%, respectively, compared to untreated infected
cells. Importantly, in the presence of both antibody and TB the inhibition was higher
with respect to that obtained by single treatment (about 65% [P  0.001 versus
untreated infected cells]), suggesting that TB may prevent the cell-to-cell spreading of
HSV-1.
TB inhibits the attachment of the virus to host cell. Next, we investigated the
antiviral activity of TB during the very early phases of HSV-1 life cycle, i.e., the
attachment and penetration phases. To this aim, two different tests were performed: (i)
an attachment assay, during which the virus can only bind the surface of the host cells
but does not enter the cell, in the presence or absence of TB, and (ii) an entry assay,
during which the peptide was added immediately after virus attachment to assess its
ability to prevent entry. As shown in Fig. 4A, the HSV-1 titer was significantly reduced
by about 2 logs and 1 log in the attachment and entry assays, respectively. To confirm
that the antiherpetic efficacy of TB was greater during the attachment phase of virus life
cycle and to exclude the possibility that TB could alter the binding of the virus to the
host cell by interfering with some receptors on the cell surface, cell monolayers were
pretreated with the peptide for 3 h at 37°C before HSV-1 infection. Supernatants of
FIG 1 (A) Cytotoxic (CC50) and (B) antiviral (IC50) effects of TB on Vero cells. (A) Cell monolayers were
incubated with increasing concentrations of the compound for 24 h, and cell proliferation was deter-
mined by an MTT assay. The CC50 of TB was calculated by regression analysis of the dose-response curve.
(B) HSV-1-infected cells were treated with the peptide at concentrations ranging from 0.1 to 40 g/ml, and
viral titer inhibition was calculated by plaque reduction assay. The IC50 of the compound was calculated by
regression analysis as described in Materials and Methods. Values are expressed as means  the SD from
three experiments, each performed in duplicate.
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FIG 2 TB reduces HSV-1 replication at different stages of the virus life cycle. A time-of-addition assay was
performed. TB was added to Vero cells as a single dose (during adsorption [ADS] or after adsorption for
the following 24 h [POST]) and as double doses (ADSPOST). Supernatants were subjected to a standard
plaque assay to evaluate viral production (upper panel). Data are expressed as means the SD from four
independent experiments, each performed in duplicate (*, P 0.05 versus untreated sample). Cell lysates
were analyzed by Western blotting with anti-HSV-1 and anti-gB antibodies; tubulin was used as a loading
control (lower panel). Densitometric analysis of gB levels is shown in the graph under the representative
Western blot, and data are expressed as means  the SD from three independent experiments (*, P 
0.05 versus untreated cells).
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infected cells were recovered 24 h after infection and used for standard plaque assay.
No difference in viral replication between untreated and TB-pretreated cells was
observed (Fig. 4B), suggesting that TB does not exert any activity on the host cell
surface.
TB possesses virucidal properties. To verify the potentially direct effect of TB on
virions, HSV-1 was preincubated with TB (HSV-1TB) or no TB (HSV-1) for 1 h at 37°C,
and then the mixtures were used to infect the cells. Immediately after virus adsorption,
the cells were washed, followed by incubation for 24 h with fresh medium. The
supernatant of the infected cells was used to perform a standard plaque assay, while
the cell monolayer was harvested and subjected to Western blot analysis of viral
proteins. Surprisingly, the plaques count showed that TB reduced by 5 log the HSV-1
titer compared to the untreated infected cells (Fig. 5A, below the gel). This strong
reduction corresponds to 99.99% inhibition of HSV-1 replication, suggesting that TB
acts directly on viral particles. These data were also confirmed by the almost complete
absence of viral proteins in HSV-1TB samples compared to HSV-1 samples (Fig. 5A).
To confirm the direct effect of TB on HSV-1 particles, a high multiplicity of infection
(MOI) of HSV-1 (20-fold higher than the standard conditions, i.e., 20 MOI) were prein-
cubated with 20 g/ml TB at 37°C for 1 h. The mixture was then diluted to 1 MOI and
used to infect cells. After viral adsorption, the cells were incubated with fresh medium
supplemented with carboxymethyl cellulose (CMC), and a plaque reduction assay was
performed. As shown in Fig. 5B, although in this assay the TB/HSV-1 ratio was altered
compared to standard experimental procedures, the peptide was able to significantly
reduce plaque formation (2-log inhibition). These results support a direct effect of TB
on HSV-1 particles that is probably due to its interaction with some components of the
viral envelope and/or to disruption of the external viral layer (virucidal effect).
FIG 3 TB inhibits HSV-1 cell-to-cell spread. Vero cells were seeded in 96-well plates, infected with HSV-1
(MOI  0.1), and treated or not treated with TB during and after viral adsorption. Anti-HSV-1 antibody
( HSV-1) at 10 g/ml was added for 24 h postinfection. Foci of infection were visualized by immuno-
staining with mouse anti-gB and IRDye 800CW goat anti-mouse antibodies. A representative image of
one of three experiments is shown in the upper panel. The relative fluorescence intensity was detected
with the LI-COR Odyssey infrared imaging system, quantified using LI-COR Image Studio Software, and
reported in the graph (in the lower panel) as the percent viral titer inhibition (**, P 0.01; ***, P 0.001).
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To verify this hypothesis, we decided to study the morphology of virus particles
(incubated or not with TB) by transmission electron microscopy (TEM). In Fig. 6Aa, the
image of HSV-1 is shown. All viral components (envelope, tegument, and nucleocapsid)
were clearly visible and intact. In contrast, in TB-pretreated HSV-1 virions a loss of viral
envelope integrity is evident (Fig. 6Ab and c), confirming the virucidal effect of TB on
HSV-1 virions. Afterward, to check whether such virucidal effect was an exclusive
property of TB, we tested the activity of another member of the temporins family, i.e.,
TA (FLPLIGRVLSGIL-NH2; Selleck Chemicals, Houston, TX) for comparison. Note that TA
previously showed activity against different viruses (19). Like TB, TA is also a peptide
with an alpha-helical structure in membrane-mimicking environments and has a net
charge of 2 at neutral pH and a length of 13 amino acids (Fig. 6) (16). TA was able to
interfere with HSV-1 replication when it was preincubated with the viral particles at
37°C for 1 h, but this inhibition was lower than that of TB (1 log versus 5 log) (data not
shown). Importantly, when the effect of TA on viral particles was visualized by electron
microscopy, no disruption of the viral envelope was detected (Fig. 6Ad and e). Finally,
to confirm whether TB was able to disrupt the envelope of the virus, we decided to
incubate more viral particles with TB and quantified the virions that were broken by the
peptide (Fig. 6B). Many TB-pretreated HSV-1 virions lost or showed a broken envelope
(ca. 88.8%  7.6% or 8.2%  5.3%, respectively), whereas ca. 2.9%  2.3% of the
virions were still intact (P  0.05, intact versus disrupted envelope). All of these results
strongly indicate that TB is effective in inhibiting viral replication by disrupting HSV-1
envelope.
FIG 4 TB inhibits HSV-1 attachment to the host cells. (A) In the attachment assay, Vero cells were infected with a
combination of HSV-1 plus TB, and inoculated cultures were kept for 1 h at 4°C to allow virus attachment but not entry.
A plaque reduction assay was then performed. In the entry assay, cells were infected and kept at 4°C for 1 h to allow virus
attachment. After a washing step, TB was added to the cells, and the cultures were incubated for 1 h at 37°C to allow HSV-1
penetration. After a single wash with PBS (pH 3) to remove eventually attached virus particles from the cell surface, the
cells were subjected to a plaque reduction assay. Viral titers, expressed as PFU/ml in the graph, are means  the SD from
three independent experiments, each performed in duplicate (**, P  0.01 versus untreated samples). For plaques stained
with crystal violet, the results of one representative experiment of three performed are shown. (B) Vero cells were
pretreated with the peptide for 3 h at 37°C before HSV-1 infection. Conditioned medium samples were collected 24 h after
infection and subjected to a standard plaque assay. Data are means  the SD from four experiments, each performed in
duplicate.
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TB reduces HSV-1 titer in human epithelial cells. On the basis of the obtained
results, TB has emerged as a promising anti-HSV-1 agent. Thus, we tested its activity on
two different human epithelial cells, HeLa S3 and HEK-293, already used for HSV-1
studies (21, 22). First, the potential cytotoxic effect of TB was evaluated by the MTT
assay. As shown in Fig. 7A, no toxicity was observed at concentrations as high as 50
g/ml TB. The IC50s were 93 and 84 g/ml for HeLa S3 and HEK-293 cells, respectively.
Viral replication was then assayed with or without TB. The results demonstrated that TB
was also effective against HSV-1 replication in both human epithelial cell lines (Fig. 7B).
In particular, the peptide reduced plaque formation by about 2 logs when it was added
during the adsorption phase. The strongest effect (an 5-log reduction) was observed
when the peptide was preincubated with HSV-1 virions for 1 h at 37°C, confirming
virucidal activity of TB.
DISCUSSION
We have demonstrated here for the first time that the AMP TB exerts significant
anti-HSV-1 activity, mainly through its direct virucidal properties. Previous mechanistic
studies on the antimicrobial effect of temporins against bacteria or fungi demonstrated
that their activity is related to disruption of the microbial membrane (23, 24). Several
authors have reported that certain defensins, cationic peptides that exert their antimi-
crobial activity through membrane permeabilization of the invading microorganism
(25), also display antiviral activity against various enveloped DNA or RNA viruses,
including HSV-1, HSV-2, cytomegalovirus, vesicular stomatitis virus, and influenza virus
A/WSN (9, 26–29). However, these peptides are not able to inactivate two nonenvel-
oped viruses: echovirus 11 and reovirus 3. The same authors suggested that the
defensins interact with the viral envelope, causing lipid bilayer perturbation (27). Also,
amphibian AMPs, such as dermaseptins, have been reported to inhibit HSV-1 and HSV-2
replication (30, 31). The mechanism of action seemed to be related to their character-
istic cationic charge. Indeed, ionic interactions between positively charged amino acids
present in the peptide sequence and the negatively charged sulfate and carboxyl
groups in heparan sulfate of cell surface proteoglycans (cellular receptors for viral B and
C glycoproteins) could block the attachment of the virus to the host cell (31). With
regard to the temporins, Chincar et al. (19) showed the ability of the isoform A to inhibit
FIG 5 TB exerts a virucidal effect. (A) HSV-1 (MOI  1) was preincubated with TB at 37°C for 1 h, and the mixture
was used to infect Vero cells for 24 h. Infected cellular monolayers were used for a Western blot assay, which was
performed with an HSV-1 antibody. Supernatants were collected, and their viral content was quantified as PFU/ml
by a standard plaque assay, as reported under the Western blot image. (B) HSV-1 (MOI 20) was preincubated with
TB at 37°C for 1 h, and the mixture was diluted 20-fold (to obtain an MOI of 1) before infection. A standard plaque
assay was performed. Data are means  the SD from four experiments, each performed in duplicate (**, P  0.01
versus untreated cells).
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channel catfish virus and frog virus 3 replication, although the mechanism of action
remains to be determined. Here, we report that TB exhibited high anti-HSV-1 activity,
particularly when preincubated alone with herpesvirus particles prior to cell infection,
thus causing disruption of the viral envelope, as observed by TEM analysis. In compar-
ison, TA did not affect HSV-1 envelope integrity. The differences in primary structure
position of the single basic residue (Arg7 in TA and Lys10 in TB [see Fig. 6]) and the
FIG 6 TB disrupts the HSV-1 envelope. (A) TB or TA peptides were incubated with HSV-1 (1  106 PFU) virions for 1 h at 37°C as
described in Materials and Methods. The morphology of the viral particles was analyzed by TEM and compared to that of untreated
particles. Images were saved at 130,000 magnification; (B) HSV-1 (5  106 PFU) was incubated with TB as described previously.
Images were saved at 180,000 magnification. The images are representative of results obtained from duplicates of two independent
experiments. Helical wheel projections of TB and TA are also shown (green, yellow, and orange symbols refer to nonpolar, polar
uncharged, and basic residues, respectively).
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hydrophobicity of the two peptides (16) are factors that may account for the ability of
TB to destroy the viral envelope in comparison to TA. This is in accordance with
literature data showing a greater tendency for TB to destabilize both anionic and
zwitterionic membranes (32). Note that viral envelope contains lipid rafts that have
been reported to regulate surface charge and protein localization and to be responsible
for the electrostatic interaction with cationic peptides (33, 34). Importantly, while the
mode of action of AMPs against bacterial cells has already been well characterized and
studied, their antiviral mechanism is not yet fully understood. Nevertheless, according
to the proposed model of destabilization of influenza virus envelope, peptide mole-
cules may insert into and disrupt the lipid bilayer after electrostatic interaction with the
viral capsid. This would be followed by disruption of the viral envelope with leakage of
viral components (35).
TB treatment also affected the attachment phase of HSV-1 cycle, but this inhibition
was more modest with respect to TB/HSV-1 preincubation. The reason for this trend
could be related to the weakly cationic nature of the peptide due to the presence of
only one basic residue (lysine) in its sequence. However, despite the weak cationic
character, the interactions between the peptide and the host cell surface might partially
affect the virus attachment to the host cell. When cell monolayers were pretreated for
3 h with TB and then infected with HSV-1, no viral titer impairment was observed with
respect to untreated cells, indicating that the inhibitory activity of TB is not due to its
interference with the cellular receptors. Interestingly, when TB was added during the
viral adsorption phase, the HSV-1 titer reduction was similar to that observed during
the attachment assay, thus supporting the ability of the peptide to inhibit the very early
stage of the viral multiplication cycle.
Furthermore, we also found out that administration of TB to the cells during the
postinfection phase could inhibit HSV-1 infection. TB-induced HSV-1 inhibition was
more pronounced when two consecutive doses of the peptide, i.e., during the viral
adsorption and postinfection phases, were used. These data suggest that TB can also
exert its antiviral activity by affecting one or more cellular targets that the virus exploits
for promoting its life cycle. Indeed, it is known that HSV-1, like other viruses, manipu-
lates host cell machinery and metabolism to its advantage (36–38). Some AMPs exert
their antibacterial activity through additional targets regulating essential biochemical
reactions, e.g., RNA, protein, or DNA biosynthesis and/or inhibition of cytosolic enzymes
(39). Accordingly, in our experimental system, when TB was added as double doses
(ADSPOST), we observed a strong reduction in ICPs and late viral protein expression,
including gB. It is important to note that this glycoprotein, as well as others, is involved
FIG 7 Cytotoxic (CC50) (A) and antiviral (B) effects of TB on human cells. (A) Confluent monolayers of HeLa S3 and HEK-293 cells were incubated with increasing
concentration of TB for 24 h, and cell proliferation was determined by an MTT assay. The TB CC50 was calculated by regression analysis of the dose-response
curve. (B) TB (20 g/ml) was added to HeLa S3 and HEK-293 cells during HSV-1 adsorption (ADS) or after viral adsorption for the following 24 h (POST). HSV-1
was also preincubated with 20 g/ml TB at 37°C, and the mixture was used to infect human cells for 24 h (TB/HSV-1, 37°C). Supernatants were subjected to
a standard plaque assay to evaluate viral production. Data are means  the SD from three independent experiments, each performed in duplicate (*, P  0.05;
**, P  0.01; ***, P  0.001 versus untreated sample).
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in the cell-to-cell spread of HSV-1 (20), and we found that TB is able to prevent spread
from infected cells to neighboring uninfected cells. Therefore, we hypothesize that the
peptide, by impairing gB expression, may interfere with HSV-1 spreading.
Due to the multiplicity of targets, AMPs are considered less likely to induce resis-
tance mechanisms in microbes than conventional drugs (40). Regarding HSV-1, the
available antiviral drugs to fight the viral infections are acyclovir and its derivatives, but,
unfortunately, immunocompromised patients who require longer-term anti-HSV ther-
apy can develop drug resistance (7). Thus, the search for new antiviral agents acting on
both viral particles and cell pathways useful for the virus may control HSV-1 infection
and bypass pharmacological resistance. In this scenario, TB can be considered a
promising preventive or therapeutic antiherpetic agent, especially for topical usage. Of
note, recent technological breakthroughs have sharply raised interest in the use of
peptides as efficacious and safe new therapeutics (39, 41). This is confirmed by the
increasing number of antitumor and/or antiviral AMPs, which is expected to lead to a
shake up in their current scenario, moving such AMPs from clinical experimentation to
the marketplace (42). Thanks to advances in nanotechnology, it is possible to conjugate
peptides to nanocarriers in order to protect them from proteolytic degradation and
prolong their bioavailability (43). In addition, the development of nanoformulations has
contributed to optimize peptide delivery to the target site (44–47). The use of peptide-
based drugs, mainly for the topical treatment of infections, is thus conceivable.
MATERIALS AND METHODS
Peptide. Synthetic TB (LLPIVGNLLKSLL-NH2) was supplied at a purity of 98% by Selleck Chemicals,
as previously reported (48). Briefly, the peptide was synthesized by standard Fmoc methodology and
purified by reversed-phase high-pressure liquid chromatography on a semipreparative C18-bonded silica
column (Kromasyl; 5 m, 100 Å, 25 cm by 4.6 mm) using a gradient of acetonitrile in 0.1% aqueous
trifluoroacetic acid at a flow rate of 1.0 ml/min.
Cell culture and virus production. African green monkey (Vero) cells were grown in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.3 mg/ml L-glutamine, 100
U/ml penicillin, and 100 g/ml streptomycin at 37°C in an atmosphere of 5% of CO2. Human embryonic
kidney (HEK-293) cells and human cervix epithelial (HeLa S3) cells were grown in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% FBS, 0.3 mg/ml L-glutamine, 100 U/ml penicillin, and 100
g/ml streptomycin. All reagents were purchased from Sigma-Aldrich. Virus production was performed
as previously reported (49). Briefly, monolayers of Vero cells in 75-cm2 tissue culture flasks were infected
with HSV-1 (strain F) at an MOI of 0.01. After 48 h at 37°C, the needed time to observe the virus-induced
cytopathic effect, infected cells were harvested using three freeze-thaw cycles, cellular debris was
removed by low-speed centrifugation for 10 min, and the virus titer was measured in the supernatants
by a standard plaque assay, as described below. The titer of the virus preparation was 5  108 PFU/ml.
The virus was stored at –80°C until use.
Cellular toxicity assays. The cellular toxicity of TB was evaluated by a trypan blue (0.02% final
concentration) exclusion assay (50). The viability and growth of Vero, HEK-293, and HeLa S3 cells were
tested in vitro by an MTT assay, as previously reported (51, 52). Briefly, cell monolayers were incubated
with TB at concentrations of 1, 10, 20, 50, 75, and 100 g/ml (corresponding to 0.72, 7.2, 14.4, 36, 54, and
72 M, respectively) in culture medium for 24 h; the medium was replaced with 50 l of a 1-mg/ml
solution of MTT in RPMI or DMEM without phenol red (Sigma-Aldrich). Cells were incubated at 37°C for
3 h, and then 100 l of acidified isopropanol (0.1 N HCl in isopropanol) was added to each well. After a
few minutes at room temperature to ensure that all crystals were dissolved, the plates were read using
an automatic plate reader with a 550-nm test wavelength and a 690-nm reference wavelength. The CC50,
defined as the drug concentration required for reducing the cell viability by 50%, was calculated by
regression analysis of the dose-response curve generated from the data.
In vitro HSV-1 infection. Vero, HeLa S3, and HEK-293 cells were seeded in 24-well plates at a density
of 1.5  105 cells/ml and infected with HSV-1 at an MOI of 1. After incubation for 1 h at 37°C to allow
virus adsorption to the host cells (adsorption phase), the medium was removed and replaced with fresh
medium supplemented with 2% FBS, and the plates were maintained for 24 h at 37°C in an atmosphere
of 5% CO2 (postinfection phase).
Determination of viral yields. The virus titer was measured using a standard plaque assay as
previously described (53, 54). Briefly, supernatants of infected samples were used at different dilutions to
infect monolayers of Vero cells. After 1 h at 37°C, the monolayers were washed, the medium was replaced
with RPMI containing 2% CMC and 2% FBS, and the plates were maintained at 37°C for 48 to 72 h until
plaque formation. The CMC solution was then removed, and the monolayers were fixed with cold
methanol for 20 min at 	20°C, washed with phosphate-buffered saline (PBS), and stained with a 0.5%
crystal violet solution. The plaques were counted, and the virus titer was calculated as PFU/ml.
To assay antiviral activity, a plaque reduction assay was performed as previously described, with
some modifications (55). Vero cells were seeded in 24-well plates at a density of 1.5  105 cells/well. The
next day, confluent cell monolayers were infected with HSV-1 at an MOI of 1 for 1 h at 37°C. The
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unabsorbed virus was subsequently removed by washing the cells three times with PBS, and the medium
was replaced with RPMI 1640 containing 1% CMC, 2% FBS, and different concentrations of TB. After
further incubation at 37°C for 36 to 48 h, the cells were fixed with cold methanol and stained with 0.5%
crystal violet solution, and the viral plaques were counted. The concentration yielding a 50% reduction
in plaque formation (IC50) was determined by regression analysis using GraphPad Prism v6.0 software by
fitting a variable slope-sigmoidal dose-response curve.
Pretreatment assay. Vero cells were incubated with TB at 20 g/ml for 3 h at 37°C, washed with PBS,
and infected with HSV-1 at an MOI of 1 for 24 h. The supernatants of infected cells were used to
determine the virus titer in a standard plaque assay.
Time-of-addition assay. TB (20 g/ml) was added to a confluent monolayer of Vero cells infected
with HSV-1 (MOI 1) at different times of infection, as follows: (i) only during the viral adsorption period
(1 h, 37°C); (ii) immediately after the adsorption period and maintained for the following 24 h; and (iii)
during the viral adsorption period (1 h, 37°C) and immediately after the adsorption period for the
following 24 h. HSV-1-infected HEK-293 and HeLa S3 cells were treated with TB (20 g/ml) during the
viral adsorption period (1 h, 37°C) or immediately after the adsorption period and maintained for
the following 24 h. The supernatants from infected cells were used to determine the virus titer using a
standard plaque assay, as described above.
Attachment assay. An attachment assay was performed as previously described (56), with some
modifications. Briefly, Vero cells were incubated with a combination of TB and HSV-1 (MOI  1) for 1 h
at 4°C. The cells were then washed twice with PBS to remove both unattached virus and peptide and
maintained for 1 h at 37°C in RPMI (adsorption phase). The cells were then washed three times with PBS,
followed by incubation for 36 h at 37°C with RPMI 1640 containing 1% CMC and 2% FBS to perform the
plaque reduction assay. Monolayers were then fixed with cold methanol and stained with 0.5% crystal
violet solution, and the plaques were counted to determine the virus titer.
Entry assay. The entry assay was performed as previously reported (57), with some modifications.
Briefly, confluent monolayers of Vero cells were infected with HSV-1 at an MOI of 1 for 1 h at 4°C. The
cells were then incubated at a higher temperature (37°C) to maximize the penetration of virus in the
presence or absence of TB. After 1 h, the supernatants were removed, and the cells were treated with PBS
(pH 3) for 1 min to neutralize any remaining attached virus. After four washes with serum-free RPMI 1640,
the cells were overlaid with medium containing 1% CMC and 2% FBS, followed by incubation at 37°C for
36 h to perform a plaque reduction assay. The monolayers were then fixed with cold methanol and
stained with crystal violet solution, and the plaques were counted to determine the viral titer.
Cell-to-cell spread assay. The assay of the cell-to-cell spread of HSV-1 was performed as previously
reported (58, 59), with some modifications. Briefly, Vero cells were seeded in 96-well plates and infected
with HSV-1 at an MOI of 0.1 for 1 h at 37°C in the presence of TB (20 g/ml, first dose). Cell monolayers
were washed, and the medium was replaced with fresh medium containing TB (20 g/ml, second dose)
and 10 g/ml anti-HSV-1 antibody (AbD Serotec) to neutralize HSV-1 particles released from infected
cells and to ensure that HSV-1 infection was actually due to cell-to-cell virus spread. As controls, Vero cells
were infected with HSV-1 and treated or not treated with neutralizing HSV-1 antibody or with TB. At 24
h postinfection, the cells were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilized in
0.1% Triton X-100–PBS for 5 min at room temperature. After incubation with Odyssey blocking buffer for
1 h at room temperature, the cells were incubated with mouse anti-gB (Santa Cruz; 1:1,000 dilution in
Odyssey blocking buffer) for 1 h at room temperature. After three washes, the cells were incubated with
labeled secondary antibody IRDye 800 CW goat anti-mouse (LI-COR Biosciences, 1:1,000 dilution in
Odyssey blocking buffer) for 1 h at room temperature (54). Finally, the plate was scanned on an LI-COR
Odyssey infrared imaging system, and the relative fluorescence intensity of each well was read by using
LI-COR Image Studio software developed for Odyssey analysis. The obtained images represented the foci
of HSV-1 infection (green).
HSV-1/temporin preincubation. TB (20 g/ml) was preincubated with HSV-1 (MOI  1) at 37°C for
1 h, and the mixture was used to infect cellular monolayers. After viral adsorption for 1 h at 37°C, the
plates were washed, and the medium was replaced with fresh medium containing 1% CMC and 2% FBS
for 36 h at 37°C. The virus titer was evaluated as already described.
Western blot analysis. Infected Vero cells, treated or not treated with TB, were washed with PBS,
recovered, and centrifuged at 770  g for 10 min., The pellet was suspended in cold lysis buffer (10 mM
Tris-HCl, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, phosphatase inhibitor mixture, 1% Triton
X-100 [pH 7.4]; Sigma-Aldrich) and incubated on ice for 30 min. After centrifugation (10,000  g for 30
min) the supernatants were collected and assayed to determine the protein concentration (Bradford
method; Bio-Rad). Equivalent amounts of proteins were suspended in sodium dodecyl sulfate (SDS)
sample buffer containing 100 mM 1,4-dithiothreitol (Sigma-Aldrich), boiled at 100°C for 10 min, sepa-
rated by SDS-PAGE, and blotted onto nitrocellulose membranes for a Western blot assay. The membranes
were blocked with 10% nonfat dry milk (Bio-Rad) in Tris-buffered saline–0.1% Tween for 1 h at room
temperature. Primary antibodies (anti-herpes simplex virus 1/2 [AbD Serotec], raised against ICPs and late
structural viral proteins; anti-gB [Santa Cruz Biotechnology]) were added at a final concentration of
1 g/ml and maintained overnight at 4°C. Secondary antibodies were horseradish peroxidase-
conjugated (Jackson ImmunoResearch). Blots were developed with ECL-Plus detection system (Thermo
Scientific) and subjected to densitometric scanning.
TEM. Transmission electron microscopy (TEM) analysis was performed as described by Bultmann et
al. (60) with some modifications. Briefly, for negative staining, a 10-l drop of HSV-1 (1  106 or 5  106
PFU) containing TB or TA suspension, previously incubated at 37°C for 1 h, was placed on a carbon-
coated grid for 30 s. Subsequently, the grid was washed with several droplets of phosphotungstic acid
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solution (2% [wt/vol], pH 6.8). The last droplet of staining solution was left for 10 s and then blotted with
filter paper. The grid was then allowed to air dry before examination. For each condition, several grids
were examined using a Philips CM 100 transmission electron microscope at an accelerating voltage of
100 kV (Microscopy Center, University of L’Aquila, L’Aquila, Italy). Ninety viral particles were examined.
Statistical analysis. Unpaired data were analyzed with a Student t test, and P values of 0.05 were
considered significant. Data are presented as means  the standard deviations (SD).
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